Lisdexamfetamine API Manufacturers

Looking for Lisdexamfetamine API 608137-32-2?

Description:

Here you will find a list of producers, manufacturers and traders of Lisdexamfetamine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Lisdexamfetamine 

Synonyms:

Lisdexamfetamine , lisdexamfetamine dimesylate  

Cas Number:

608137-32-2 

DrugBank number:

DB01255 

Unique Ingredient Identifier:

H645GUL8KJ

Lisdexamfetamine is a type of Amphetamine

Amphetamine is a potent central nervous system (CNS) stimulant and a key pharmaceutical active pharmaceutical ingredient (API) subcategory widely used in the medical field. It belongs to the class of substituted phenethylamines and is known for its stimulating effects on the brain and body.

Amphetamine is primarily prescribed to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. It works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain, leading to improved focus, attention, and wakefulness.

The pharmacological properties of amphetamine make it highly effective in enhancing cognitive function and reducing symptoms associated with ADHD. Furthermore, it helps individuals with narcolepsy by promoting alertness and preventing sudden sleep attacks.

When used as an API, amphetamine is carefully synthesized, purified, and formulated into various pharmaceutical products, such as tablets or capsules. Strict quality control measures ensure the potency, safety, and consistency of the API.

It is worth noting that amphetamine is a controlled substance due to its potential for misuse and addiction. Therefore, its production, distribution, and use are closely monitored and regulated by government authorities to prevent abuse.

In summary, amphetamine is a widely recognized pharmaceutical API subcategory that plays a crucial role in the treatment of ADHD and narcolepsy. Its stimulant properties, coupled with its carefully controlled synthesis and formulation, make it an essential component of numerous pharmaceutical products that positively impact the lives of many individuals.

Lisdexamfetamine (Amphetamine), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Chr. Olesen Group from Denmark, product country of origin Denmark
• Tofigh Daru from Iran, product country of origin Iran
• Noramco from United States, product country of origin United States
• Embio from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.